Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents

Cancer Investigation

Volumn 27, Issue 2, 2009, Pages 221-226

  Aragon Ching, Jeanny B ^a   Ning, Yang Min ^a   Chen, Clara C ^b   Latham, Lea ^a   Guadagnini, Jean Pierre ^c   Gulley, James L ^a   Arlen, Philip M ^a   Wright, John J ^a   Parnes, Howard ^a   Figg, William D ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Anti angiogenesis; Bisphosphonates; Chemotherapy; Osteonecrosis of the jaw; Prostate pancer

Indexed keywords

ALENDRONIC ACID; BEVACIZUMAB; CHLORHEXIDINE GLUCONATE; DOCETAXEL; IBANDRONIC ACID; PREDNISONE; TECHNETIUM; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ANTIBIOTIC THERAPY; ARTICLE; BONE DISEASE; BONE NECROSIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMAGING; INCIDENCE; JAW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOUTH HYGIENE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT;

ADULT; AGED; ALENDRONATE; ANGIOGENESIS INHIBITORS; DIPHOSPHONATES; HUMANS; INCIDENCE; JAW DISEASES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEONECROSIS; PROSTATIC NEOPLASMS;

EID: 60849105693     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802208608     Document Type: Article

References (33)

1. Weitzman, R.; Sauter, N.; Eriksen, E.F.;Tarassoff, P.G.; Lacerna, L.V.; Dias, R., et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit Rev Oncol Hematol 2007, 62(2), 148-152.
2. Marx, R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003, 61(9), 1115-1117.
3. Ruggiero, S.L.; Mehrotra, B.; Rosenberg, T.J.; Engroff, S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004, 62(5), 527-534.
4. Bagan, J.; Blade, J.; Cozar, J.M.; Constela, M.; Garcia Sanz, R.; Gomez Veiga, F., et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Pathol Oral Cir Bucal 2007, 12(4), E336-340.
5. Burr, D.B. Summary of ASBMR Task Force on ONJ. J Musculoskelet Neuronal Interact 2007, 7(4), 354-355.
6. Schwartz, H.C. Osteonecrosis of the jaws: A complication of cancer chemotherapy. Head Neck Surg 1982, 4(3), 251-253.
7. Marx, R.E.; Sawatari, Y.; Fortin, M.; Broumand, V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63(11), 1567-1575.
8. Woo, S.-B.; Hellstein, J.W.; Kalmar, J.R. Systematic Review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144(10), 753-761.
9. Woo, S.B.; Hande, K.; Richardson, P.G. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005, 353(1), 99-102; discussion 199-102.
10. Wang, J.; Goodger, N.M.; Pogrel, M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. JOral Maxillofac Surg 2003, 61(9), 1104-1107.
11. Marymont, J.V.; Kaufman, E.E. Osteonecrosis of bone associated with combination chemotherapy without corticosteroids. Clin Orthop Relat Res 1986, (204), 150-153.
12. Obrist, R.; Hartmann, D.; Obrecht, J.P. Osteonecrosis after chemotherapy. Lancet 1978, 1(8077), 1316.
13. Estilo, C.L.; Van Poznak, C.H.; Williams, T.; Evtimovska, E.; Tkach, L.; Halpern, J.L., et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study. J Clin Oncol (Meeting Abstracts) 2004, 22(14 suppl), 8088.
14. Bamias, A.; Kastritis, E.; Bamia, C.; Moulopoulos, L.A.; Melakopoulos, I.; Bozas, G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23(34), 8580-8587.
15. Ning, Y.M.; Gulley, J.; Arlen, P.; Latham, L.; Srinavasan, R.; Wright, J., et al. A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic castration-refractory prostate cancer (CRPC). ASCO Genitourinary Cancers Symposium, San Francisco, 2008, Abstract # 164.
16. Cavanna, L.; Berte, R.; Arcari, A.; Mordenti, P.; Pagani, R.; Vallisa, D. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Intern Med 2007, 18(5), 417-422.
17. Mashiba, T.; Mori, S.; Burr, D.B.; Komatsubara, S.; Cao, Y.; Manabe, T., et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005, 23 Suppl, 36-42.
18. Scavelli, C.; Di Pietro, G.; Cirulli, T.; Coluccia, M.; Boccarelli, A.; Giannini, T., et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007, 6(12), 3256-3262.
19. Santini, D.; Caraglia, M.; Vincenzi, B.; Holen, I.; Scarpa, S.; Budillon, A., et al. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 2006, 3(6), 325-338.
20. Ferretti, G.; Fabi, A.; Carlini, P.; Papaldo, P.; Felici, A.; Tomao, S., et al. Zoledronic acid and angiogenesis. Clin Cancer Res 2007, 13(22 Pt 1), 6850; author reply 6850-6851.
21. Wood, J.; Bonjean, K.; Ruetz, S.;Bellahcene, A.; Devy, L.; Foidart, J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302(3), 1055-1061.
22. Fournier, P.; Boissier, S.; Filleur, S.; Guglielmi, J.; Cabon, F.; Colombel, M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62(22), 6538-6544.
23. Garcia Saenz, J.A.; Lopez Tarruella, S.; Garcia Paredes, B.; Rodriguez Lajusticia, L.; Villalobos, L.; Diaz Rubio, E. Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Pathol Oral Cir Bucal 2007, 12(5), E351-356.
24. Wang, E.P.; Kaban, L.B.; Strewler, G.J.; Raje, N.; Troulis, M.J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007, 65(7), 1328-1331.
25. Ortega, C.; Faggiuolo, R.; Vormola, R.; Montemurro, F.; Nanni, D.; Goia, F., et al. Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncol 2006, 45(2), 216-217.
26. Ortega, C.; Montemurro, F.; Faggiuolo, R.;Vormola, R.; Nanni, D.; Goia, F., et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis. Acta Oncol 2007, 46(5), 664-668.
27. Saad, F.; Gleason, D.M.; Murray, R.;Tchekmedyian, S.; Venner, P.; Lacombe, L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94(19), 1458-1468.
28. Aapro, M.; Abrahamsson, P.A.; Body, J.J.; Coleman, R.E.; Colomer, R.; Costa, L., et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008, 19(3), 420-432.
29. Zervas, K.; Verrou, E.; Teleioudis, Z.; Vahtsevanos, K.; Banti, A.; Mihou, D., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 2006, 134(6), 620-623.
30. Durie, B.G.M.; Katz, M.; Crowley, J.; Woo, S.-B.; Hande, K.; Richardson, P.G., et al. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005, 353(1), 99-102.
31. Zanglis, A.; Andreopoulos, D.; Dima, M.; Baltas, G.; Baziotis, N. Jaw uptake of technetium-99 methylene diphosphonate in patients on biphosphonates: A word of caution. Hell J Nucl Med 2007, 10(3), 177-180.
32. Chiandussi, S.; Biasotto, M.; Dore, F.; Cavalli, F.; Cova, M.A.; Di Lenarda, R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006, 35(4), 236-243.
33. Khan, S.A.; Kanis, J.A.; Vasikaran, S.; Kline, W.F.; Matuszewski, B.K.; McCloskey, E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12(10), 1700-1707.